“Bimekizumab Efficacy through Year 1 in Patients With Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3 3B Trials”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 2, Mar. 2024, p. s369, https://doi.org/10.25251/skin.8.supp.369.